Author Archives: Dan Liu

Hatch-Waxman Litigation in a Nutshell Hatch-Waxman litigation refers to pharmaceutical patent litigation between a brand drug manufacturer and a generic drug manufacturer under the Hatch-Waxman Act (“Act”). The Act was enacted to facilitate generic drug entry into the market while … Continue reading

Posted in Patent Litigation | Tagged , , , , , , , | Comments Off on Emerging Impact of Inter Partes Review on Hatch Waxman Litigation – A Primer

Six days after the Supreme Court handed down its opinion in Alice Corp. v. CLS Bank, which invalidated certain patents disclosing “a computer-implemented scheme for mitigating ‘settlement risk,’” the USPTO issued its own Preliminary Examination Instructions. (An overview of the … Continue reading

Posted in Patent Litigation | Tagged , , , , | Comments Off on The USPTO’s Response to Alice Corp. v. CLS Bank

In two related decisions, the Supreme Court relaxed the standard to award attorney’s fees under Section 285 of the Patent Act (“§285”) and ruled that decisions on §285 are entitled to deference on appeal.  In the first case, the Court … Continue reading

Posted in Patent Litigation | Tagged , , , | Comments Off on The Supreme Court Gave District Courts more Power to Award Attorney’s Fees in Patent Litigation